… respiratory syndrome coronavirus (MERS-CoV), … protease inhibitors. With the recent reporting
of the X-ray crystal structure of the SARS-CoV-2 M pro , studies to discover M pro inhibitors …

… crystal structure of SARS-CoV-2 M pro in complex with the protease inhibitor PF-07321332
reveals critical insight for pharmaceutical development. With the emergence of SARS-CoV-2 …

… SARS-CoV-2 M pro activity assay, we screened a collection of protease inhibitors, such as
reported M pro inhibitors … human immunodeficiency virus (HIV) protease inhibitors. At 10 μM, …

… This section summarizes the research progress of SARS-CoV-2 M pro inhibitors. … development
based on cysteine protease inhibitors, whose significance is not limited to SARS-CoV-2. …

… inhibitors of SARS-CoV 3CL pro . Attempts have been made to provide a complete description
of the structural features and binding modes of these inhibitors under many conditions. …

… The viruses responsible for the SARS outbreak in 2002/2003 and the ongoing COVID-19
pandemic are called SARS coronavirus (SARS-CoV) and SARS coronavirus 2 (SARS-CoV-2), …

… Protease inhibitors targeting viral 3C-like protease are … deuterated variants of a
coronavirus protease inhibitor, GC376, … severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), …

… that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease …
Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection …

… capable of binding a variety of viral proteases, including SARS-CoV-2 M pro and PL pro ,
EV… to bind and inhibit additional proteases such as the SARS-CoV-2 papain-like protease (PL …

… The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV… , nonpeptidic SARS-CoV-2 3CL protease inhibitor clinical …